2017
DOI: 10.15403/jgld.2014.1121.264.ski
|View full text |Cite
|
Sign up to set email alerts
|

Adherence to an Acotiamide Therapeutic Regimen Improves Long-Term Outcomes in Patients with Functional Dyspepsia

Abstract: Background & Aims: Long-term outcomes in patients with functional dyspepsia remain elusive. Acotiamide, a prokinetic drug, has been available in Japan since 2013. The aim of this study was to assess long-term outcomes in patients with functional dyspepsia treated with acotiamide.Methods: We retrospectively reviewed 79 consecutive patients with functional dyspepsia whose symptoms improved with acotiamide therapy and who were followed for more than one year. All patients underwent esophagogastroduodenoscopy … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
3
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 18 publications
0
3
0
1
Order By: Relevance
“…In a European study of patients with FD, dyspepsia symptoms recurred within 3 months in 20% of the patients whose symptoms had disappeared after 4 weeks of treatment with a PPI or placebo [86]. Similarly, in a Japanese study of patients with FD whose symptoms improved with acotiamide therapy, FD was found to have recurred in 25% of the patients at 1 year [87]. In a population-based cohort study in the United States of the impact of FGIDs on survival with over 30,000 person-years of follow-up, no association with overall survival was detected for dyspepsia, IBS, chronic diarrhea, or abdominal pain; only chronic constipation was related to poorer survival [88].…”
Section: Prognosis and Complicationsmentioning
confidence: 99%
See 1 more Smart Citation
“…In a European study of patients with FD, dyspepsia symptoms recurred within 3 months in 20% of the patients whose symptoms had disappeared after 4 weeks of treatment with a PPI or placebo [86]. Similarly, in a Japanese study of patients with FD whose symptoms improved with acotiamide therapy, FD was found to have recurred in 25% of the patients at 1 year [87]. In a population-based cohort study in the United States of the impact of FGIDs on survival with over 30,000 person-years of follow-up, no association with overall survival was detected for dyspepsia, IBS, chronic diarrhea, or abdominal pain; only chronic constipation was related to poorer survival [88].…”
Section: Prognosis and Complicationsmentioning
confidence: 99%
“…In a European study of patients with FD, dyspepsia symptoms recurred within 3 months in 20% of the patients whose symptoms had disappeared after 4 weeks of treatment with a PPI or placebo [ 86 ]. Similarly, in a Japanese study of patients with FD whose symptoms improved with acotiamide therapy, FD was found to have recurred in 25% of the patients at 1 year [ 87 ].…”
Section: Clinical Statementmentioning
confidence: 99%
“…A definitive strategy for functional dyspepsia without heartburn remains unclear. Although this study demonstrates that the effectiveness of VPZ is comparable to ACO, once daily treatment with VPZ may be preferable since this regimen may improve long-term compliance that is important to maintain long-term control [14]. Vonoprazan is administered both before and after a meal once daily, but ACO is only taken before meals three times daily.…”
Section: Discussionmentioning
confidence: 92%
“…Чаще всего они отмечались при очень выраженной клинической картине ФД (отношение шансов (ОШ) составило 15,04; р = 0,013). Продолжение приема акотиамида в течение года достоверно уменьшало частоту рецидивов (ОШ = 0,16; р = 0,004) [18].…”
Section: эффективность акотиамида в лечении пациентов с функционально...unclassified